QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
OTCMKTS:APLIF

Appili Therapeutics - APLIF Stock Forecast, Price & News

$0.04
0.00 (0.00%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.06
52-Week Range
$0.04
$0.90
Volume
N/A
Average Volume
32,015 shs
Market Capitalization
$2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APLIF stock logo

About Appili Therapeutics (OTCMKTS:APLIF) Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

Appili Therapeutics GAAP EPS of -C$0.38
Appili Therapeutics launches securities offering
Aditxt Signs Share Exchange Agreement to Acquire AiPharma
Appili Therapeutics – Press Release Correction
Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc Class A
APLIF: PRESECO Trial Unsuccessful in COVID-19…
See More Headlines
Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Company Calendar

Today
10/04/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-20,040,000.00
Pretax Margin
-1,417.91%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
($0.04) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.78 million
Optionable
Not Optionable
Beta
-0.70

Key Executives

  • Dr. Armand Balboni J.D. (Age 56)
    M.D., Ph.D., CEO & Director
    Comp: $279.7k
  • Dr. Yoav Golan M.S. (Age 60)
    M.D., MS, Chief Medical Officer
    Comp: $248.56k
  • Dr. Donald D. Cilla Jr.
    M.B.A., Pharm.D., Pharmd, Chief Devel. Officer
  • Mr. Kenneth G. Howling
    Acting Chief Financial Officer













APLIF Stock - Frequently Asked Questions

Should I buy or sell Appili Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Appili Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" APLIF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APLIF, but not buy additional shares or sell existing shares.
View APLIF analyst ratings
or view top-rated stocks.

How have APLIF shares performed in 2022?

Appili Therapeutics' stock was trading at $0.09 at the beginning of 2022. Since then, APLIF stock has decreased by 56.7% and is now trading at $0.0390.
View the best growth stocks for 2022 here
.

Are investors shorting Appili Therapeutics?

Appili Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 78,200 shares, a decrease of 33.2% from the August 31st total of 117,100 shares. Based on an average daily volume of 46,100 shares, the short-interest ratio is presently 1.7 days.
View Appili Therapeutics' Short Interest
.

When is Appili Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APLIF earnings forecast
.

What is Appili Therapeutics' stock symbol?

Appili Therapeutics trades on the OTCMKTS under the ticker symbol "APLIF."

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Appili Therapeutics' stock price today?

One share of APLIF stock can currently be purchased for approximately $0.04.

How much money does Appili Therapeutics make?

Appili Therapeutics (OTCMKTS:APLIF) has a market capitalization of $2.78 million and generates $1.11 million in revenue each year. The company earns $-20,040,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

How can I contact Appili Therapeutics?

Appili Therapeutics' mailing address is 21-1344 SUMMER ST., HALIFAX A5, B3H 0A8. The official website for the company is www.appilitherapeutics.com. The company can be reached via phone at 902-442-4655.

This page (OTCMKTS:APLIF) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.